145 related articles for article (PubMed ID: 25808917)
1. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Tiribelli M; Binotto G; Calistri E; Maino E; Scaffidi L; Medeot M; Nabergoj M; Ambrosetti A; Semenzato G; Fanin R; Bonifacio M;
Am J Hematol; 2015 Jul; 90(7):E135-7. PubMed ID: 25808917
[No Abstract] [Full Text] [Related]
2. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
Kim DD; Hamad N; Lee HG; Kamel-Reid S; Lipton JH
Am J Hematol; 2014 Jun; 89(6):626-32. PubMed ID: 24619861
[TBL] [Abstract][Full Text] [Related]
3. Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia.
Lee SE; Choi SY; Oh YJ; Kim SH; Song HY; Yoo HL; Lee MY; Chae MJ; Kang KH; Hwang HJ; Jang EJ; Kim DW
Leuk Res; 2015 Apr; 39(4):411-8. PubMed ID: 25680524
[TBL] [Abstract][Full Text] [Related]
4. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
[TBL] [Abstract][Full Text] [Related]
5. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
7. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
[No Abstract] [Full Text] [Related]
8. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
[TBL] [Abstract][Full Text] [Related]
9. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
10. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
[TBL] [Abstract][Full Text] [Related]
11. The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.
Breccia M; Finsinger P; Loglisci G; Latagliata R; Mancini M; Salaroli A; Serrao A; Zacheo I; Alimena G
Leuk Res; 2012 Sep; 36(9):e209-10. PubMed ID: 22770911
[No Abstract] [Full Text] [Related]
12. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
Sayed D; Badrawy H; Gaber N; Khalaf MR
Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
[TBL] [Abstract][Full Text] [Related]
13. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Tchirkov A; Couderc JL; Périssel B; Goumy C; Regnier A; Uhrhammer N; Verrelle P; Berger M
Leukemia; 2006 Jan; 20(1):167-8. PubMed ID: 16270035
[No Abstract] [Full Text] [Related]
14. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Ashariati A; Ugroseno S
Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
[TBL] [Abstract][Full Text] [Related]
15. [Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
Huang Q; Zhang XY; Li Y; Wang XM
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3049-53. PubMed ID: 24417926
[TBL] [Abstract][Full Text] [Related]
16. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
18. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
19. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Tiribelli M; Bonifacio M; Calistri E; Binotto G; Maino E; Marin L; Guardalben E; Branca A; Gherlinzoni F; Semenzato G; Sancetta R; Pizzolo G; Fanin R
Leuk Res; 2013 Nov; 37(11):1457-60. PubMed ID: 23993428
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
